MedTrace Logo

MyopiaX Treatment for the Reduction of Myopia Progression in Children and Adolescents: Safety and Efficacy Investigation

NCT04967287 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2024-10-28

No results posted yet for this study

Summary

The purpose of this trial is to investigate the safety and efficacy of MyopiaX - a digital treatment intended to slow the progression of myopia in children and adolescents.

Conditions

  • Myopia

Interventions

DEVICE

MyopiaX

MyopiaX treatment twice a day

DEVICE

Myopia control spectacles

To be used all as prescribed

Sponsors & Collaborators

  • Dopavision GmbH

    lead INDUSTRY

Principal Investigators

  • Ian Flitcroft, Prof. · Centre for Eye Reserach Ireland, Technological University Dublin

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-16
Primary Completion
2024-10-04
Completion
2024-10-04

Countries

  • Germany
  • Netherlands
  • Portugal
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04967287 on ClinicalTrials.gov